跳至主要内容
临床试验/PACTR202206902932545
PACTR202206902932545已完成未知

DROTAVERINE HYDROCHLORIDE VERSUS HYOSCINE BUTYLBROMIDE IN REDUCING FIRST STAGE OF LABOUR AMONG NULLIPARAE : A RANDOMIZED CONTROLLED TRIA

nenna S Nweke0 个研究点目标入组 165 人开始时间: 2022年3月10日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
165

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19 Year(s) 至 44 Year(s)(—)
性别
Female

入选标准

  • 1.Nulliparae
  • 2.Women who consented to participate in the study
  • 3.Women with fetus in cephalic presentation
  • 4.Singleton fetus with no evidence of maternal or fetal distress.
  • 5.Women with no contraindication to vaginal delivery.
  • 6.Term pregnancies with intact or ruptured membranes
  • 7.Cervical dilatation of 4-5 cm only
  • 8.Spontaneous or induced labour
  • 9.Patients on epidural

排除标准

  • 1 Women with abnormal fetal presentation.
  • 2. Women in latent phase of labour.
  • 3. Preterm / term premature rupture of membranes.
  • 4. Antepartum haemorrhage.
  • 5. Those who refused to consent.
  • 6. Previous uterine scar or surgery.
  • 7. Huge fibroid in pregnancy.
  • 8. Multiple gestations.
  • 9. Multiparous or grand multiparous patients.
  • 10. Medical diseases in pregnancy such as severe preeclampsia/eclampsia and others.
  • 11. History of cervical surgery.
  • 12. Hypersensitivity to drotaverine hydrochloride.
  • 13. Any contraindication to vaginal delivery

研究者

发起方
nenna S Nweke

相似试验